- Home
- JANX vs DJCO Comparison
JANX vs DJCO Comparison
Compare JANX & DJCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | DJCO |
|---|---|---|
| Founded | 2017 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.3M | 706.2M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | JANX | DJCO |
|---|---|---|
| Price | $15.18 | $540.09 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $50.09 | N/A |
| AVG Volume (30 Days) | ★ 929.9K | 74.1K |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.50 |
| EPS | ★ N/A | N/A |
| Revenue | $10,000,000.00 | ★ $41,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.12 | $348.63 |
| 52 Week High | $35.34 | $674.75 |
Technical Indicators
Market Signals| Indicator | JANX | DJCO |
|---|---|---|
| Relative Strength Index (RSI) | 61.72 | 57.85 |
| Support Level | $13.10 | $385.04 |
| Resistance Level | $15.49 | $557.95 |
| Average True Range (ATR) | 0.57 | 26.68 |
| MACD | 0.09 | 5.12 |
| Stochastic Oscillator | 86.29 | 87.28 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.